Lupin Limited has marked its debut in the Chinese market following the approval of its Abbreviated New Drug Application for Oseltamivir Phosphate oral suspension. Partnering with Yabao Pharmaceuticals, Lupin aims to expand access to high-quality paediatric medicines. This significant milestone in the company’s global expansion follows the product’s official clearance by China’s National Medical Products Administration, aimed at treating and preventing influenza in paediatric and adult populations.
Strategic Market Expansion
On May 22, 2026, Lupin announced a major breakthrough in its global growth strategy by securing regulatory approval in China. By collaborating with Yabao Pharmaceuticals, a leader in the Chinese paediatric medicine sector, Lupin has successfully established its first product presence in the region. This partnership leverages Lupin’s pharmaceutical expertise and Yabao’s strong commercial footprint to deliver critical medications to children and adults in need.
Product Efficacy and Purpose
The approved product, Oseltamivir Phosphate for oral suspension (6 mg/mL), serves dual clinical purposes. It is indicated for the treatment of influenza A and B in patients as young as 2 weeks old and above, and for the prevention of influenza A and B in individuals 1 year of age and older. This medication addresses a vital need within the paediatric healthcare landscape, ensuring access to essential therapies.
Collaborative Future Growth
Lupin and Yabao Pharmaceuticals intend to utilize this momentum to further strengthen their collaboration. Both companies are committed to expanding their R&D portfolios, with a specific focus on developing innovative paediatric and adult chronic disease drugs. This partnership not only accelerates Lupin’s entry into one of the world’s largest pharmaceutical markets but also aligns with its long-term vision of enhancing patient outcomes globally through high-quality, affordable healthcare solutions.
Source: BSE
